Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterization of Tremor in Children Using Accelerometry and The Kinarm.
Movement Disorders
P15 - Poster Session 15 (12:00 PM-1:00 PM)
3-005

We aim to better characterize tremor in children from a clinical, neurophysiological and kinematic perspective.


Tremor is one of the most common movement disorders during childhood. Growing evidence outlines the importance to implement ancillary assessment methods that allow quantification of its basic kinematic features. Nevertheless, the majority of tremor research pertains exclusively to an adult population.


a cross sectional study was performed in a tertiary pediatric movement disorders clinic. Ten consecutive patients with essential tremor(ET) were assessed. Clinical evaluation was performed utilizing the Tremor Rating Scale (TRS). Subsequently, triaxial accelerometers were placed equidistantly at the dorsum of the hands and arms, the recording was done during 90 second intervals within  various tasks and different arm positions following the TRS protocol. Kinematic evaluation was performed with a validated reaching task protocol from the Kinarm exoskeleton.


Mean age was 13.4 SD 1.9 years, 77.8% were males.  Mean age at onset of tremor was 8.5 SD 5.05 years. Mean TRS score was 9.3 SD 7.1.  Principal component analysis of the accelerometers with a subsequent Fast Fourier Transform revealed mean median frequencies in the 0-30hz band power of 16.1 SD 3.7hz arms extended and 16.7 SD 3.4 hz within finger to nose maneuvers. Comparison of patients with tremor with a matched age and handedness control group in the Kinarm reaching task yielded significant differences in maximum speed(0.1498m/s±0.036m/s vs 0.1869m/s ±0.035m/s, respectively; p<0.05).


To the best of our knowledge this is the first study demonstrating kinematic differences in children with ET. It remains to be determined if these differences could be attributed to motor compensatory mechanisms or be part of the intrinsic components of ET.


Authors/Disclosures
Alex J. Medina Escobar, MD (The Moncton City Hospital)
PRESENTER
No disclosure on file
Nicholas Cothros, MD (Kingston Health Sciences Centre) No disclosure on file
Davide Martino, MD, PhD (Department of Clinical Neurosciences, University of Calgary) Dr. Martino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Martino has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merz Pharma Canada Ltd..
No disclosure on file
Adam Kirton, MD (Alberta Children'S Hospital) Dr. Kirton has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Multiple. The institution of Dr. Kirton has received research support from Multiple.
Emmanuel Roze, MD, PhD Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for merz. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving as a Consultant for orkyn. Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for elivie. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for allergan. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Orkyn. Dr. Roze has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for elivie. Dr. Roze has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aguettant. The institution of Dr. Roze has received research support from merz. The institution of Dr. Roze has received research support from Orkyn. Dr. Roze has received research support from elivie. The institution of Dr. Roze has received research support from allergan. The institution of Dr. Roze has received research support from fondation desmarest. The institution of Dr. Roze has received research support from everpharma. Dr. Roze has received research support from AMADYS. The institution of Dr. Roze has received research support from ADCY5.org. The institution of Dr. Roze has received research support from agence nationale de la recherche. The institution of Dr. Roze has received research support from société française de médecine esthétique. The institution of Dr. Roze has received research support from dystonia medical research foundation.
No disclosure on file
Tamara M. Pringsheim, MD, FÂé¶¹´«Ã½Ó³»­ (Mathison Centre) The institution of Dr. Pringsheim has received research support from Canadian Institutes of Health Research. The institution of Dr. Pringsheim has received research support from Azrieli Accelerator.